
## Mark Opler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9370608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP). Schizophrenia Research, 2021, 228, 529-533.	2.0	6
2	Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients. Nordic Journal of Psychiatry, 2021, 75, 454-464.	1.3	5
3	Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). Schizophrenia Research, 2021, 228, 438-446.	2.0	2
4	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. Journal of Psychopharmacology, 2021, 35, 1081-1090.	4.0	9
5	Discrepancies between staff and gold standard ratings of schizophrenia symptom severity. Psychiatry Research, 2021, 301, 113963.	3.3	1
6	Clinical Validation of the Autism Behavior Inventory: Caregiver-Rated Assessment of Core and Associated Symptoms of Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2020, 50, 2090-2101.	2.7	14
7	M35. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6). Schizophrenia Bulletin, 2020, 46, S147-S148.	4.3	2
8	S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS. Schizophrenia Bulletin, 2020, 46, S131-S132.	4.3	0
9	The brief negative symptom scale in translation: A review of psychometric properties and beyond. European Neuropsychopharmacology, 2020, 33, 36-44.	0.7	14
10	T22. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6). Schizophrenia Bulletin, 2019, 45, S211-S212.	4.3	2
11	T45. THE NEW YORK ASSESSMENT OF ADVERSE COGNITIVE EFFECTS OF NEUROPSYCHIATRIC TREATMENT (NY-AACENT): INITIAL VALIDATION FINDINGS. Schizophrenia Bulletin, 2019, 45, S221-S221.	4.3	0
12	A new brief opioid stigma scale to assess perceived public attitudes and internalized stigma: Evidence for construct validity. Journal of Substance Abuse Treatment, 2019, 99, 44-51.	2.8	47
13	Cross-cultural adaptation of the Arabic Positive and Negative Syndrome Scale in schizophrenia: Qualitative analysis of a focus group. Transcultural Psychiatry, 2019, 56, 973-991.	1.6	6
14	The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophrenia Research, 2018, 197, 269-273.	2.0	17
15	Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI). Nordic Journal of Psychiatry, 2018, 72, 431-436.	1.3	17
16	Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 2017, 190, 74-76.	2.0	11
17	Autism Behavior Inventory: A Novel Tool for Assessing Core and Associated Symptoms of Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 814-822.	1.3	37
18	177. Autism Behavior Inventory – A Novel Tool for Assessment of Changes in Core and Associated Symptoms of Autism Spectrum Disorder. Biological Psychiatry, 2017, 81, S73-S74.	1.3	0

MARK OPLER

#	Article	IF	CITATIONS
19	Validation of the Five-Factor Model of the Arabic Version of the Positive and Negative Syndrome Scale in Schizophrenia. Psychopathology, 2017, 50, 211-218.	1.5	7
20	Validity and Reliability of the Arabic Version of the Positive and Negative Syndrome Scale. Psychopathology, 2016, 49, 181-187.	1.5	16
21	Reliability, validity and factorial structure of the Arabic version of the international suicide prevention trial (InterSePT) scale for suicidal thinking in schizophrenia patients in Doha, Qatar. BMC Psychiatry, 2016, 16, 437.	2.6	6
22	Validation of the Arabic Version of Calgary Depression Scale for Schizophrenia. PLoS ONE, 2016, 11, e0162304.	2.5	15
23	Job Burnout, Mood State, and Cardiovascular Variable Changes of Doctors and Nurses in a Children's Hospital in China. ISRN Nursing, 2014, 2014, 1-6.	1.2	11
24	Risk of schizophrenia and minority status: A comparison of the Swedish-speaking minority and the Finnish-speaking majority in Finland. Schizophrenia Research, 2014, 159, 303-308.	2.0	15
25	Comments on the scoring guideline of the Personal and Social Performance Scale (PSP). Schizophrenia Research, 2014, 152, 304.	2.0	2
26	Effect of parental age on treatment response in adolescents with schizophrenia. Schizophrenia Research, 2013, 151, 185-190.	2.0	8
27	A new Integrated Negative Symptom structure of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia using item response analysis. Schizophrenia Research, 2013, 150, 185-196.	2.0	20
28	Prenatal stress and affective disorders in a population birth cohort. Bipolar Disorders, 2013, 15, 92-99.	1.9	61
29	Environmental Risk Factors and Schizophrenia. International Journal of Mental Health, 2013, 42, 23-32.	1.3	11
30	Assessing the Sources of Unreliability (Rater, Subject, Time-Point) in a Failed Clinical Trial Using Items of the Positive and Negative Syndrome Scale (PANSS). Journal of Clinical Psychopharmacology, 2013, 33, 109-117.	1.4	17
31	Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. NeuroToxicology, 2012, 33, 560-574.	3.0	82
32	ADVANCED PATERNAL AGE CONTRIBUTES TO A SPECIFIC SUBTYPE OF SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S3.	2.0	2
33	Poster #188 A RASCH MODEL ANALYSIS TO ASSESS CROSS-CULTURAL DIFFERENCES AMONG ITEMS THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) IN SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S253.	2.0	0
34	Olfactory processing, sex effects and heterogeneity in schizophrenia. Schizophrenia Research, 2012, 135, 144-151.	2.0	37
35	Emotional and Neurobehavioural Status in Chronic Pain Patients. Pain Research and Management, 2011, 16, 41-43.	1.8	13
36	Epidemiology Research and Epigenetics: Translational Epidemiology of Schizophrenia. , 2011, , 71-96.		0

MARK OPLER

#	Article	IF	CITATIONS
37	Later paternal age and sex differences in schizophrenia symptoms. Schizophrenia Research, 2010, 116, 191-195.	2.0	42
38	Primary psychiatric prevention in children and adolescents. Annals of Clinical Psychiatry, 2010, 22, 220-34.	0.6	13
39	Prostate Cancer in Fathers With Fewer Male Offspring: the Jerusalem Perinatal Study Cohort. Journal of the National Cancer Institute, 2007, 99, 77-81.	6.3	22
40	Secretin's role in the cerebellum: A larger biological context and implications for developmental disorders. Cerebellum, 2006, 5, 2-6.	2.5	1
41	Abnormal phospholipid metabolism in schizophrenia: evidence from epidemiological findings, clinical observations, and preliminary clinical trials. Frontiers in Bioscience - Landmark, 2001, 6, e61.	3.0	3
42	Reduced dopamine levels in PC12 cells exposed to low frequency electromagnetic fields. Bioelectrochemistry, 1997, 42, 235-239.	1.0	14
43	Biological and technical variables in myc expression in HL60 cells exposed to 60 Hz electromagnetic fields. Bioelectrochemistry, 1997, 44, 111-120.	1.0	31
44	Electromagnetic field exposure induces rapid, transitory heat shock factor activation in human cells. Journal of Cellular Biochemistry, 1997, 66, 482-488.	2.6	98